Three years in a row! Medicilon once again appears on the 2023 "Influential Preclinical CRO Enterprises of the Year" list

On December 15, the 4th China Biopharmaceutical Industry Chain Innovation and Transformation Summit and the 4th China Biopharmaceutical Innovation Billboard Awards Ceremony were grandly held in Hangzhou.

This is the third consecutive year that Medicilon has won this award!

As an important force in promoting and participating in the development of the biopharmaceutical industry, it is particularly meaningful for Medicilon to win this honor again on the occasion of its 20^th anniversary.  This heavy honor is a tribute to Medicilon’s continuous efforts and pioneering efforts in the field of biomedical preclinical R&D in the past 20 years.  It is also recognition of Medicilon's active exploration of cutting-edge fields such as nucleic acid drugs, cellular immunity, mRNA, PROTAC, ADC, bi/multi-specific antibodies and the establishment of innovative service platforms.  It also fully affirms Medicilon’s one-stop biopharmaceutical preclinical R&D service platform for successfully accelerating the clinical approval of 385 INDs.  At the same time, this honor also inspires Medicilon to overcome difficulties and make new achievements.